Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Core Insights - Carisma Therapeutics has announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna [1][2][3] Group 1: Therapy Development - The anti-GPC3 CAR-M therapy demonstrates specificity for the GPC3 tumor antigen, showing potent dose-dependent cytotoxicity against GPC3+ tumor cells [2] - Systemic administration of the therapy significantly reduced tumor burden and suppressed liver metastasis in both syngeneic and humanized tumor models [2] - The therapy was well tolerated in mouse models, indicating its potential as an off-the-shelf treatment for GPC3+ solid tumors, including HCC [2] Group 2: Technological Innovation - The therapy utilizes mRNA/LNP technology to generate anti-GPC3 CAR-M cells directly in vivo, leading to significant tumor reduction in relevant pre-clinical models [3] - The successful application of the mRNA/LNP platform highlights its potential in enabling in vivo cell therapy [3] Group 3: Company Overview - Carisma Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies using its proprietary macrophage and monocyte cell engineering platform [4]